Category: Bayer HealthCare
Medical device company Conceptus agrees to a $1.1 billion buyout by German healthcare conglomerate Bayer AG.
Conceptus (NSDQ:CPTS) agreed to a buyout by Bayer (PINK:BAYRY) in a deal valued at $1.1 billion.
French healthcare giant Sanofi is the last buyer still in the running to acquire German Bayer's blood glucose management devices, a deal that may be worth more than $1.5 billion, sources say.
Medtronic's new insulin pumps will include Bayer's next-generation Contour Next Link wireless blood glucose meter.
MASSDEVICE ON CALL — Medtronic (NYSE:MDT) insulin pumps will all come with the next-generation Contour Next Link wireless blood glucose meter from Bayer (PINK:BAYRY).
High rates of tobacco use in China and Japan could be a windfall for heart device makers; also, don't forget reimbursement, says a Bayer exec; device makers keep a cool head in a tough market; Echo Therapeutics spikes deal with MLV & Co.; DSM commences $360M tender offer for Kensey Nash; Texas health provider to include NeuroMetrix's neuropathy test in all facilities; Notre Dame U. and Cleveland Clinic join forces to market novel products; AngioDynamics shareholders approve stock issuance for Navilyst acquisition; Surgline International buys Eden Surgical Tech.; plus, a Funding Roundup and analysts' ups and downs.
The Chinese medical device market may triple by 2018, partially due to high rates of tobacco consumption and a rapidly growing economy, according to a market report.
HeartWare announced that it completed enrollment in a 450-patient clinical trial considering its HVAD pump as a destination therapy for patients with advanced heart failure; also, 2011 was a good year for angel investment; Bayer considers ditching diabetes business; iCad gets a stay of execution from Nasdaq delisting; INC Research expands a electronic data management partnership with Medidata; and Kimberly Clark renews a sterilization wrap contract with HealthTrust; plus, a Funding Roundup and analysts' ups and downs.
HeartWare International (NSDQ:HTWR) completed enrollment in a 450-patient pivotal trial considering its ventricular assist system as a destination therapy for patients with advanced heart failure.
Medtronic is shutting down its 55-person Ventor operation in Israel, according to a news report; also, Femasys inks Japanese distribution deal with Bayer for FemVue system; Medtronic discloses 7% stake in REVA Medical; Empire exits MSI Surgical; GPOs: Premier inks ortho deal with Emerge; and analysts' ups and downs.
Medtronic (NYSE:MDT) is shutting down heart valve maker Ventor Technologies, which it acquired in 2009, and moving its R&D efforts to other site, according to an Israeli business journal.
Netanya, Israel-based Ventor is developing an aortic replacement valve called the Engager. Medtronic bought the company for $325 million 3 years ago.